Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$7.53 USD

7.53
124,923

-0.38 (-4.80%)

Updated Aug 25, 2026 03:42 PM ET

After-Market: $7.51 -0.02 (-0.27%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

by Zacks Equity Research

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Zacks Equity Research

Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

by Zacks Equity Research

Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

Zacks Equity Research

Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

by Zacks Equity Research

The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.

Zacks Equity Research

Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.

Zacks Equity Research

GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use

by Zacks Equity Research

GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.

Zacks Equity Research

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

by Zacks Equity Research

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Zacks Equity Research

Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU

by Zacks Equity Research

Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.

Zacks Equity Research

Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails

by Zacks Equity Research

The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.

Kinjel Shah headshot

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Nilanjan Choudhury headshot

Relative Price Strength Makes These 5 Stocks Excellent Buys

by Nilanjan Choudhury

WING, JAKK, NSIT, GIII and DERM are five stocks with explosive relative price strength.